Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Cannara Biotech (LOVE) Stock Price & Analysis

41 Followers

LOVE Stock Chart & Stats

CA$2.01-CA$0.02(-0.99%)
At close: 4:00 PM EST
C$2C$2.1C$2.2Aug 17Aug 31Sep 14Sep 28Oct 13Oct 26Nov 9
Day’s Range
CAD 2.00 - CAD 2.03
52-Week Range
CAD 1.55 - CAD 2.37
Previous Close
CAD 2.03
Volume
N/A
Average Volume (3M)
34.70K
Market Cap
CAD 200.53M
Enterprise Value
CAD 183.06M
Total Cash (Recent Filing)
CAD 21.81M
Total Debt (Recent Filing)
CAD 37.00M
Price to Earnings (P/E)
17.7
Beta
0.51
Next Earnings
Nov 24, 2026 (Est.)
EPS Estimate
0.04
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Sustained double-digit revenue growth indicates expanding demand and improving distribution rather than a one-time gain. Continued top-line scaling can support operating leverage, strengthen brand presence, and provide resources for capacity investment over the next several quarters.

Consistent Profitability And Cash Generation

A long record of positive adjusted EBITDA and operating cash flow demonstrates that the operating model is generating recurring financial support for the business. This consistency improves resilience and reduces reliance on external funding as Cannara expands.

Capacity And Distribution Expansion

Accelerated production expansion combined with broad distribution gives Cannara a larger platform to capture regulated-market demand. The existing-footprint runway toward 100,000 kg could support future volume growth while wider availability reinforces market access and brand velocity.

Bears Say

Margin Compression And Earnings Volatility

Recent margin deterioration shows that revenue growth has not translated consistently into operating profitability. Product mix and cost pressure could limit earnings conversion, making future results more sensitive to pricing, cultivation efficiency, and the pace of operational improvement.

Expansion Is Reducing Free Cash Flow

Large expansion investments are absorbing cash even while the company remains profitable, reducing near-term financial flexibility. If capital spending continues ahead of capacity benefits, lower free cash flow could constrain debt reduction, reinvestment choices, or the ability to absorb weaker trading.

Competitive Pricing And Category Pressure

Intensifying competition can make distribution gains more expensive and weaken realized pricing or volumes in important categories. Higher marketing requirements and targeted price adjustments may therefore limit margin sustainability even as Cannara expands its product reach.

Cannara Biotech News

LOVE FAQ

What was Cannara Biotech’s price range in the past 12 months?
Cannara Biotech lowest stock price was C$1.55 and its highest was C$2.37 in the past 12 months.
What is Cannara Biotech’s market cap?
Cannara Biotech’s market cap is C$200.53M.
When is Cannara Biotech’s upcoming earnings report date?
Cannara Biotech’s next earnings report is estimated for Nov 24, 2026 (not yet confirmed), which is in 12 days.
How were Cannara Biotech’s earnings last quarter?
Cannara Biotech released its earnings results on Jul 15, 2026. The company reported C$0.05 earnings per share for the quarter.
Is Cannara Biotech overvalued?
According to Wall Street analysts Cannara Biotech’s price is currently Undervalued.
Does Cannara Biotech pay dividends?
Cannara Biotech does not currently pay dividends.
What is Cannara Biotech’s EPS estimate?
Cannara Biotech’s EPS estimate is 0.04.
How many shares outstanding does Cannara Biotech have?
Cannara Biotech has 98,782,150 shares outstanding.
What happened to Cannara Biotech’s price movement after its last earnings report?
Cannara Biotech reported an EPS of C$0.05 in its last earnings report. Following the earnings report the stock price went down -1.053%.
Which hedge fund is a major shareholder of Cannara Biotech?
Currently, no hedge funds are holding shares in TSE:LOVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology